Study on the value of tumor markers ProGRP, CYFRA21-1, NSE and CEA in the differential diagnosis of pleural effusion

Chinese Journal of Lung Cancer

Volumn 9, Issue 3, 2006, Pages 273-276

  Liu, Yunqiu ^a   Yu, Liqun ^b   Lin, Jiangtao ^b  

^a Kailuan Hospital   (China)

^b NONE

Author keywords

CEA; CYFRA21 1; Lung neoplasms; NSE; Pleural effusion; ProGRP; Tumor marker

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; NEURON SPECIFIC ENOLASE; PROGASTRIN RELEASING PEPTIDE; TUMOR MARKER;

ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; HISTOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; PLEURA EFFUSION; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; YOUDEN INDEX;

EID: 33745758101     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Bonner JA, Sloan JA, Rowland KM Jr, et al. Significance of neuron-specific enolase levels before and during therapy for small cell lung cancer. Clin Cancer Res, 2000, 6(2): 597-601.
2. Fizazi K, Cojean I, Pignon JP, et al. Normal serum neuron specific enolase (NSE) value after the first cycle of chemotherapy: an early predictor of complete response and survival in patients with small cell lung carcinoma. Cancer, 1998, 82(6): 1049-1055.
3. Pujol JL, Boher JM, Grenier J, et al. Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients. Lung Cancer, 2001, 31(2-3): 221-231.
4. Plebani M, Basso D, Navaglia F, et al. Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results? Br J Cancer, 1995, 72(1): 170-173.
5. Ferrer J, Villarino MA, Encabo G, et al. Diagnostic utility of CYFRA 21-1, carcinoembryonic antigen, CA 125, neuron specific enolase, and squamous cell antigen level determinations in the serum and pleural fluid of patients with pleural effusions. Cancer, 1999, 86(8): 1488-1495.
6. Song JQ, Wu GP, Zhao M, et al. The value of the pleural effusion CYFRA21-1, NSE detection in the diagnosis of lung cancer. Chin J Lung Cancer, 2005, 8(3): 226.
7. Shibayama T, Ueoka H, Nishii K, et al. Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC). Lung Cancer, 2001, 32(1): 61-69.
8. Stieber P, Dienemann H, Schalhorn A, et al. Pro-gastrin-releasing peptide (ProGRP)-a useful marker in small cell lung carcinomas. Anticancer Res, 1999, 19(4A): 2673-2678.
9. Goto K, Kodama T, Hojo F, et al. Clinicopathologic characteristics of patients with nonsmall cell lung carcinoma with elevated serum progastrin-releasing peptide levels. Cancer, 1998, 82(6): 1056-1061.
10. Shijubo N, Hirasawa M, Sasaki H, et al. Elevated progastrin-releasing peptide (31-98) concentrations in pleural effusions due to small-cell lung carcinoma. Respiration, 1996, 63(2): 106-110.
11. Karnak D, Ulubay G, Kayacan O, et al. Evaluation of Cyfra 21-1: a potential tumor marker for non-small cell lung carcinomas. Lung, 2001, 179(1): 57-65.
12. Ebert W, Muley T. CYFRA 21-1 in the follow-up of inoperable non-small cell lung cancer patients treated with chemotherapy. Anticancer Res, 1999, 19(4A): 2669-2672.
13. Li GS. The present condition of the tumor markers of lung cancer. Tumor, 1998, 18(3): 138.
14. Lee YC, Knox BS, Garrett JE. Use of cytokeratin fragments 19.1 and 19.21 (Cyfra 21-1) in the differentiation of malignant and benign pleural effusions. Aust N Z J Med, 1999, 29(6): 765-769.
15. Lai RS, Chen CC, Lee PC, et al. Evaluation of cytokeratin 19 fragment (CYFRA 21-1) as a tumor marker in malignant pleural effusion. Jpn J Clin Oncol, 1999, 29(9): 421-424.
16. Ando S, Kimura H, Iwai N, et al. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer. Anticancer Res, 2001, 21(4B): 3085-3092.
17. Alatas F, Alatas O, Metintas M, et al. Diagnostic value of CEA, CA 15-3, CA 19-9, CYFRA 21-1, NSE and TSA assay in pleural effusions. Lung Cancer, 2001, 31(1): 9-16.
18. Ferrer J, Villarino MA, Encabo G, et al. Diagnostic utility of CYFRA 21-1, carcinoembryonic antigen, CA 125, neuron specific enolase, and squamous cell antigen level determinations in the serum and pleural fluid of patients with pleural effusions. Cancer, 1999, 86(8): 1488-1495.
19. Wu GP, Ba J, Wang EH, et al. Diagnostic value of determination of CEA, CA125, CA153 and CA199 assay in pleural fluid for lung cancer. Chin J Lung Cancer, 2004, 7(1): 35-37.
20. Liu YQ, Lin JT. The value of the carbohydrate antigen 153 and carcinoembryonic antigen detection to the diagnosis of malignant pleural effusion and benign pleural effusion. Chin J Tuberc Respir Dis, 2003, 26(8): 508-509.